Shionogi & Co., Ltd. received approval for a new drug, Nardemizin, in China, contributing to the treatment of opioid-induced constipation. The approval was granted on May 27, 2026, and further market penetration and business expansion are anticipated.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-05-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4507-20260529-01.pdf","jir_short_summary":"Shionogi & Co., Ltd. received approval for a new drug, Nardemizin, in China, contributing to the treatment of opioid-induced constipation. The approval was granted on May 27, 2026, and further market penetration and business expansion are anticipated.","jir_summary":"### Overview of Business Performance\nShionogi & Co., Ltd. obtained approval for a new drug, Nardemizin, in China. Nardemizin is a treatment for opioid-induced constipation (OIC), and it is already available in Japan, the United States, and Europe. This approval was granted based on positive results from phase 3 clinical trials by China's National Medical Products Administration (NMPA). The approval is expected to promote sales development and expansion in the Chinese market, contributing to improvements in patients' quality of life. It is anticipated that the impact on consolidated financial results for the fiscal year ending March 2027 will be minimal.\n\n### Future Outlook and Initiatives\nThrough its subsidiary, Shionogi Limited in China, Shionogi & Co., Ltd. will promote sales of Nardemizin and aim to expand its use as a treatment drug. With successful clinical trials in China, the company will strengthen adoption in medical settings and provide it to patients, aiming to improve the quality of life for those suffering from pain and side effects. Furthermore, the company considers 'contributing to healthy and fulfilling lives' an important material issue and will continue its social responsibility initiatives.","jir_financial_highlights":"Approval Date: May 27, 2026 (Unknown)\nSales responsibility region in China: Shionogi Limited in Shanghai (Unknown)\nExpected contribution to sales based on approval: Unknown (Unknown)","jir_category":"","jir_hashtags":"#ShionogiPharmaceutical, #IR, #JapanStocks","jir_key_figures":"Approval Date: May 27, 2026\nSales region: Shionogi Limited in Shanghai, China\nImpact on business results for the fiscal year ending March 2027: Minimal","jir_meta_title":"[Shionogi & Co., Ltd.] Nardemizin New Drug Approved in China | May 2026","jir_meta_description":"Shionogi & Co., Ltd. received approval for a new drug, Nardemizin, in China, contributing to the treatment of opioid-induced constipation. Expectations are high for future sales development and business expansion.","jir_og_title":"[Shionogi & Co., Ltd.] Nardemizin Approved in China | May 2026","jir_og_description":"Shionogi & Co., Ltd. has obtained approval for the new drug Nardemizin in China. The company is advancing initiatives for market dissemination and business expansion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-55418","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n